Freya Biosciences (Freya or the Firm), a transatlantic biotech firm specializing in girls’s well being, immediately publicizes a $10.4 million strategic funding from the Invoice & Melinda Gates Basis (the inspiration) with $1.4 million extra financing from present investor Export and Funding Fund of Denmark (EIFO).
The funds shall be used to develop microbial immunotherapies for the remedy of bacterial vaginosis (BV) to deal with pre-term delivery and probably different indications affecting maternal and new child well being.
Freya is creating microbial immunotherapies to control the immune system and inflammatory responses within the vaginal tract utilizing its DYSCOVER™ platform. Freya has recognized Lactobacillus strains which are able to engrafting within the vaginal tract thereby displacing the prevailing dysbiotic vaginal microbiome and decreasing key irritation biomarkers. To this point the platform has yielded Freya’s lead candidate, FB301 for bettering being pregnant success in IVF.
Freya will now leverage the DYSCOVER platform to develop and convey to the clinic a microbial immunotherapy for BV. BV is a typical situation that happens when the vagina is contaminated with micro organism, inflicting an imbalance within the native microbiome leading to disagreeable however normally gentle signs. Nevertheless, it may have critical penalties in pregnant girls, elevating the prospect of untimely rupture of membranes, preterm delivery, intra-amniotic an infection, low delivery weight and miscarriage. BV is treatable with antibiotics, however usually BV redevelops shortly after antibiotic remedy has been accomplished, finally resulting in continual recurrence and elevated irritation within the reproductive tract.
BV is a critically underserved situation, with prevalence amongst girls of reproductive age between 23–29% and better charges in sure low-and middle-income nations. Girls in these areas face disproportionately excessive dangers of preterm delivery and related problems, underscoring the worldwide want for efficient, accessible therapies. Thus, there’s an pressing have to develop a therapeutic that may serve populations around the globe, particularly these in resource-constrained settings the place the well being burden is most acute.
We’re thrilled that the Invoice & Melinda Gates Basis has positioned its belief and financing in Freya to deal with main unmet world well being challenges. This is a crucial validation of our work and the potential of the DYSCOVER platform, enabling Freya to develop critically wanted therapeutic candidates for girls’s and toddler well being.”
Colleen Acosta, PhD, Chief Govt Officer, Freya Biosciences
Peter Bisgaard, Chairman of the Board of Freya Biosciences, added: “Freya’s mission is to develop revolutionary options that may rework the well being outcomes for thousands and thousands of ladies globally, together with in low-resource settings. This strategic funding from the Invoice & Melinda Gates Basis empowers us to tackle some of the urgent points in maternal and toddler well being – bacterial vaginosis, its related irritation and connection to preterm delivery. We’re dedicated to making sure that the advantages of our breakthrough therapies lengthen to girls all over the place.”
In reference to the financing, Chris Chen, Companion, Strategic Funding Fund on the Invoice & Melinda Gates Basis, will be a part of the Freya Biosciences board of administrators as an observer, efficient instantly.
